A PHASE I TRIAL OF CLIC-2201 FOR THE TREATMENT OF RELAPSED/REFRACTORY B CELL MALIGNANCIES

Registry ID

CLIC-02

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

BC CANCER, PART OF THE PROVINCIAL HEALTH SERVICES AUTHORITY

Start date

2026-05-12

Last update

2024-07-18

Conditions

• B-CELL MALIGNANCIES

Related clinical trials

• A MODULAR PHASE I/II OPEN-LABEL DOSE ESCALATION AND DOSE EXPANSION STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, PHARMACODYNAMICS, AND EFFICACY OF AZD5492, A T CELL-ENGAGING ANTIBODY TARGETING CD20 IN SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL MALIGNANCIES (TITANIUM)
• FIRST-IN-HUMAN STUDY TO EVALUATE THE SAFETY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF THE BTK DEGRADER, ABBV-101, IN PARTICIPANTS WITH B-CELL MALIGNANCIES
• A FIRST-IN-HUMAN MULTICENTER, OPEN-LABEL STUDY TO DETERMINE THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY EFFICACY OF ABBV-319 IN B-CELL MALIGNANCIES
• A PHASE 1/2, OPEN-LABEL, DOSE-ESCALATION AND -EXPANSION STUDY OF THE BRUTON TYROSINE KINASE TARGETED PROTEIN DEGRADER BGB-16673 IN PATIENTS WITH B-CELL MALIGNANCIES
• A MULTICENTER, OPEN-LABEL, PHASE 2 BASKET STUDY TO EVALUATE THE SAFETY AND EFFICACY OF MK¿2140 AS A MONOTHERAPY AND IN COMBINATION IN PARTICIPANTS WITH AGGRESSIVE AND INDOLENT B-CELL MALIGNANCIES
• A PHASE 1/2 DOSE ESCALATION AND COHORT EXPANSION STUDY OF THE SAFETY AND EFFICACY OF ALLOGENEIC CRISPR-CAS9-ENGINEERED T CELLS (CTX110) IN SUBJECTS WITH RELAPSED OR REFRACTORY B-CELL MALIGNANCIES

View on source registry